Skip to main content

Q2 RESULT LOWERED BY MEDITERRANEAN HEADWINDS

Q2 2025 INTERIM REPORT ANNOUNCEMENT NO. 25/2025Q2 2025Revenue up 3% to DKK 7.8bn Organic growth was -2% EBIT reduced 69% to DKK 163m Adjusted free cash flow of DKK 538m CO2 ferry emission intensity from own fleet lowered 4.1%Outlook 2025EBIT of DKK 0.8-1.0bn (previously around DKK 1.0bn) Revenue growth of around 5% Adjusted free cash flow of around DKK 1.0bn (unchanged)“Most of the network performed in line with our expectations for the quarter. The Mediterranean activities remain our key earnings challenge,” says Torben Carlsen, CEO.  Q2 Q2 Change, LTM LTM Change, Full-yearDKK m 2025 2024 % 2024-25 2023-24 % 2024               Revenue 7,810 7,580 3 30,510 28,613 7 29,753EBITDA 893 1,232 -28 3,892 4,737 – 18 4,440EBIT 163 519 -69 833 1,963 – 58 1,506Adjusted free cash flow 538 724 -26 1,344 2,311 –...

Continue reading

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today. Webcast scheduled for 20 August 2025, at 09:00 (CET). Link to webcast here. Second Quarter 2025 Business Update HighlightsOn track toward IND/CTA submission in 2H 2025 and first-in-human trial initiation in 1H 2026. Broadened regulatory engagement: following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1. Initiated GMP manufacturing of clinical material in July 2025, a major step in clinical readiness; scalable platform developed with Catalent can deliver hundreds of doses from a single batch. Strong support from leading...

Continue reading

Rekordhøye andrekvartalsvolumer og -inntekter for Mowi

(Bergen, 20. august 2025) Mowi rapporterte inntekter på 1,39 milliarder euro (16,29 milliarder kroner) og et operasjonelt driftsresultat på 189 millioner euro (2,20 milliarder kroner) i andre kvartal. Andre kvartal endte med rekordhøye inntekter for Mowi for denne delen av året, som følge av sterk biologisk og operasjonell drift, rekordhøye volumer og lavere kostnader. – 2025 har vært et godt år med meget god drift og sterk vekst så langt for havbruksvirksomheten, sier konsernsjef i Mowi, Ivan Vindheim. Mowi slaktet rekordhøye 133 000 tonn i andre kvartal, som er en vekst på hele 21% sammenlignet med i fjor. Mowi øker derfor volumguidingen for 2025 fra 530 000 tonn til 545 000 tonn, som tilsvarer en vekst på 9% fra 2024. – Det er gledelig å se at vi leverer på vekststrategien vår, og med nylig inngått avtale om økt eierandel i Nova Sea...

Continue reading

Seasonally record-high volumes and revenues for Mowi in Q2

(Bergen, 20 August 2025) Mowi generated operating revenues of EUR 1.39 billion in the second quarter which translated into an operational profit of EUR 189 million. The second quarter of 2025 ended with record-high revenues for Mowi, on strong biological and operational performance, all-time high volumes and decreasing cost. “2025 has so far been a good year for the Farming division with very good operations and strong growth,” said Mowi CEO, Ivan Vindheim. Mowi harvested a record 133,000 tonnes in the second quarter, representing growth of 21% compared with last year. The company has consequently increased its volume guidance for 2025 to 545,000 tonnes on strong seawater growth, equivalent to annual growth of 9% from 2024. “It is satisfying to see that we are delivering on our strategy. With the recently concluded agreement to increase...

Continue reading

Lerøy Seafood Group ASA: Solid operations across all segments, strong earnings in VAP S&D and Wild Catch

“We delivered solid operations across all segments in the second quarter, resulting in an operational EBIT of NOK 680 million in the quarter. The quarter clearly illustrates the robustness of our business model with a fully integrated value chain in a diversified seafood company,” says CEO of Lerøy Seafood Group ASA (LSG), Henning Beltestad. FARMING – STRONG BIOLOGICAL PERFORMANCE BUT LOW PRICES FOR SALMON AND TROUT. Operational EBIT in the second quarter of 2025 ended at NOK 256 million in the Farming segment. “LSG achieved its highest net growth ever for a second quarter. Survival rates are high, the share of superior quality is high, and the average harvest weight has increased, while cost per kg is declining. This is due to a very strong biological performance. We see a more challenging start to the third quarter,...

Continue reading

Blue Moon Metals Secures up to US$140 Million Project Finance Package from Hartree/Oaktree to Advance Flagship Nussir Project in Norway

TORONTO, Ontario, Aug. 19, 2025 (GLOBE NEWSWIRE) — Blue Moon Metals Inc. (“Blue Moon” or the “Company“) (TSXV: MOON; OTCQX: BMOOF), is pleased to announce that it has entered into a memorandum of understanding with Hartree Partners, LP (“Hartree“) and funds managed by Oaktree Capital Management, L.P. (“Oaktree“, together with Hartree, the “Lenders“, and each a “Lender“) which consists of a previously agreed to bridge loan (the “Bridge Loan“) with Nussir ASA, a 93.55% owned subsidiary of the Company, as borrower, and Keystone Mines Inc., Blue Moon Norway AS and Repparfjord Eiendom AS, each a wholly owned subsidiary of the Company, as guarantors, as well as terms related a project financing package (the “Project Finance Package” and together...

Continue reading

High Arctic Announces the Executive Management Changes

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, Aug. 19, 2025 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) announces the resignation of Mr. Mike Maguire as Chief Executive officer and the appointment of Mr. Lonn Bate as Interim Chief Executive Officer, effective today, August 19, 2025. Mr. Bate has been Chief Financial Officer of the Corporation since July 1, 2024 and prior to that he has been involved with the Corporation in a consulting capacity from March 2023. In addition, the Corporation is pleased to announce the appointment of Mr. Jay Bachman as Interim Chief Financial Officer, also effective August 19, 2025, subject...

Continue reading

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment in certain non-small cell lung cancer (“NSCLC”) patients whose tumors harbor epidermal growth factor receptor (“EGFR”) mutation and MET overexpression. The last patient was enrolled on August 18, 2025. This Phase III trial is a blinded, randomized, controlled study in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression. The study will evaluate the efficacy and safety of TAGRISSO® in combination with ORPATHYS® comparing to TAGRISSO® alone, a standard-of-care...

Continue reading

OMNIQ Improves Margins and Sharpens Cost Structure in First Half of 2025

SALT LAKE CITY, Aug. 19, 2025 (GLOBE NEWSWIRE) — OMNIQ Corp. (OTCMKTS:OMQS) or “The Company” announced today the financial results of the second quarter 2025, showing a strong financial turnaround in the first half of 2025, with overall net loss reduced to just $34,000 from $5.1 million in the prior year period, and a 75 percent reduction in equity deficit on $15.7 million of revenue. All of the following values are adjusted post the announcement that was released July 16th, 2025, due to the sale of the legacy business.Stockholders’ Equity: Improved by $32.9M, reducing the deficit by approximately 75% from $(43.9M) to $(11.0M). Revenue: $15.7 million for the first half of 2025, compared to $17.5 million in the same period of 2024. Gross Margin: Improved to 26% (2025) from 23% (2024), as the company became more efficient in purchases...

Continue reading

Evolve Announces August 2025 Distributions for Certain Evolve Funds

TORONTO , Aug. 19, 2025 (GLOBE NEWSWIRE) — Evolve Funds Group Inc. (“Evolve”) is pleased to announce the distribution amounts per unit (the “Distributions”) for certain funds (the “Evolve Funds”), as indicated in the table below. The ex-dividend date and record date for the Distributions of the High Interest Savings Account Fund (“HISA”), US High Interest Savings Account Fund (“HISU.U”), Premium Cash Management Fund (“MCAD”) and US Premium Cash Management Fund (“MUSD.U”) is anticipated to be August 27, 2025. For the distributions for all other Evolve Funds, the ex-dividend date and record date is anticipated to be August 29, 2025. Unitholders of Evolve Funds on record date will receive cash distributions payable on or about September 8, 2025.Evolve Funds TickerSymbol Distributionper Unit FrequencyEvolve Canadian...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.